In a series of experiments, mice were administered the enzyme elastase to mimic COPD. It was shown that untreated JadiCell stem cells, as well as stem cells from sources conventionally utilized, specifically fat and bone marrow, had some therapeutic activity including reduction of inflammation, stimulation of regenerative growth factors, and preservation of alveoli structure1. All cell types had improved therapeutic activity when processed using the ApoptoCyte procedure, with JadiCell possessing the highest activity.
'In May of this year we announced and filed a patent on the ApoptoCyte procedure which involves the induction of cellular suicide in the stem cell, extraction of small vesicles called 'apoptotic bodies' and co-administration with specific drugs such as certain histone deacetylase (HDAC) inhibitors. Leveraging this technology, we have filed a new patent on COPD which contains the data disclosed today,' said Dr.
The Company possesses IND #28508 for using non-modified JadiCells for COPD, however the clinical trial is expected to initiate following further discussions between the Company and the FDA. Additionally, the Company currently is running a Phase III clinical trial using JadiCells for treatment of advanced COVID-19 infection.
'COPD represents a significant unmet medical need for which no curative approaches exist,' said
About
Contact:
E: ir@tsoimail.com
(C) 2022 Electronic News Publishing, source